Table 1.
Frequency of anti-Toxoplamsa IgG and IgM antibodies
| Subjects | Anti-Toxoplasma IgG antibodya |
Anti-Toxoplasma IgM antibodyb |
||
|---|---|---|---|---|
| No. cases | Seroprevalence (%) | No. cases | Seroprevalence (%) | |
| HIV/AIDS patients | 259 | 9.7 | 259 | 1.2 |
| Intravenous drug users | 90 | 2.2 | 90 | 0 |
| Healthy controls | 85 | 4.7 | 85 | 1.2 |
a
The prevalence of anti-Toxoplasma IgG antibody was significantly greater in HIV/AIDS patients than that in intravenous drug users (P<0.05), with no other significant differences observed (P>0.05).
b
There was no significant difference in the prevalence of anti-Toxoplasma IgM antibody among the three types of study subjects (P>0.05).